Cardiff Oncology Inc (CRDF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cardiff Oncology Inc (CRDF) has a cash flow conversion efficiency ratio of -0.131x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.97 Million) by net assets ($45.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cardiff Oncology Inc balance sheet independence to measure how much of total assets are equity-financed.
Cardiff Oncology Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Cardiff Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CRDF cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Cardiff Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardiff Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thinkific Labs Inc
TO:THNC
|
-0.004x |
|
Pearl Diver Credit Company Inc.
NYSE:PDCC
|
0.083x |
|
Quantum X Labs Inc.
NASDAQ:QXL
|
-0.028x |
|
Li-S Energy Ltd
AU:LIS
|
-0.023x |
|
Ilyda SA
AT:ILYDA
|
0.032x |
|
Mcleod Russel India Limited
NSE:MCLEODRUSS
|
-0.521x |
|
Smart Digital Group Limited Ordinary Shares
NASDAQ:SDM
|
N/A |
|
As Commercial Industrial Company of Computers and Toys S.A.
AT:ASCO
|
0.028x |
Annual Cash Flow Conversion Efficiency for Cardiff Oncology Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Cardiff Oncology Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see CRDF stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $45.39 Million | $-37.92 Million | -0.836x | -83.87% |
| 2024-12-31 | $82.95 Million | $-37.69 Million | -0.454x | -2.60% |
| 2023-12-31 | $69.74 Million | $-30.89 Million | -0.443x | -39.26% |
| 2022-12-31 | $106.34 Million | $-33.82 Million | -0.318x | -93.82% |
| 2021-12-31 | $140.42 Million | $-23.04 Million | -0.164x | -28.89% |
| 2020-12-31 | $128.16 Million | $-16.31 Million | -0.127x | +92.98% |
| 2019-12-31 | $7.31 Million | $-13.27 Million | -1.815x | -38.63% |
| 2018-12-31 | $10.08 Million | $-13.20 Million | -1.309x | +63.42% |
| 2017-12-31 | $6.51 Million | $-23.28 Million | -3.578x | -127.89% |
| 2016-12-31 | $19.77 Million | $-31.04 Million | -1.570x | -245.73% |
| 2015-12-31 | $48.70 Million | $-22.12 Million | -0.454x | +70.21% |
| 2014-12-31 | $8.35 Million | $-12.73 Million | -1.524x | -324.83% |
| 2013-12-31 | $20.39 Million | $-7.32 Million | -0.359x | +84.23% |
| 2012-12-31 | $2.17 Million | $-4.93 Million | -2.275x | -598.70% |
| 2011-12-31 | $-4.23 Million | $-1.93 Million | 0.456x | +9.10% |
| 2010-12-31 | $-5.00 Million | $-2.09 Million | 0.418x | +28.84% |
| 2009-12-31 | $-3.79 Million | $-1.23 Million | 0.325x | -- |
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in… Read more